Version June 2024
| Name | Formulation | Dose | Brand name | Manufacturer | WHO-prequalified* | Primary use |
| Bivalent WC | Inactivated whole cell vaccine against V. cholerae O1 and O139 | Age ≥1 year: 2-dose series (preferably 14 days apart)¶ | Euvichol, Euvichol plus | EuBiologics (Republic of Korea) | Yes | Global stockpile |
| Shanchol | Shantha Biotechnics-Sanofi Pasteur (India) | Yes | Global stockpile; production ceased in 2023 | |||
| Cholvax | Incepta Pharmaceuticals (Bangladesh) | No | Approved and licensed in Bangladesh | |||
| mORCVAX | Vabiotech (Vietnam) | No | Approved and licensed in Vietnam | |||
| WC-rBS | Inactivated whole cell vaccine against V. cholerae O1, with recombinant cholera toxin B subunit | Age 2 to 6 years: 3-dose series (1 to 6 weeks apart) Age ≥6 years: 2-dose series (1 to 6 weeks apart) | Dukoral | Valneva (Sweden) | Yes | Used for travelers from Canada and the European Union to areas of active cholera transmission Available in more than 60 countries but not in global stockpile |
| CVD 103-HgR | Live attenuated V. cholerae O1 serotype Inaba vaccine expressing cholera toxin B subunit | Age 2 to 64 years: single dose | Vaxchora | Emergent Biosolutions (USA) | No | Approved by United States Food and Drug Administration (FDA) for travelers from the United States to areas of active cholera transmission |
V. cholerae: Vibrio cholerae; WHO: World Health Organization.
* Inclusion in the WHO list of prequalified vaccines means a vaccine meets WHO vaccine quality, safety, and efficacy standards.
¶ Vaccine shortages and use in complex humanitarian emergencies often necessitate the use of a single vaccine dose or schedule delays exceeding the recommended 14-day interval.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
